# A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

> **NCT07748624** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 120 (estimated)

## Conditions studied

- VEXAS Syndrome

## Interventions

- **DRUG:** Arumakimig
- **DRUG:** Placebo
- **DRUG:** Oral glucocorticoids

## Key facts

- **NCT ID:** NCT07748624
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2028-12-26
- **Final completion:** 2031-04-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748624, "A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07748624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*